In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other unstoppable stocks that could double your money. Generating significant returns ...

In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against the other multibagger stocks. The US equities continued their upward movement in 2024 ...

Avidity Biosciences, Inc.’s RNA share price has dipped by 7.10%, which has investors questioning if this is right time to buy.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.38, along with a high estimate of $72.00 and a low estimate of $48.00. This current ...

Avidity Biosciences, Inc. (RNA) shares soared 11.3% in the last trading session to close at $29.77. The move was backed by solid volume with far more shares changing hands than in a normal session.

Avidity Biosciences (NASDAQ:RNA – Get Free Report) last announced its earnings results on Thursday, February 27th.The biotechnology company reported ($0.80) earnings per share for the quarter ...

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus recommendation of “Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports.

SAN DIEGO, April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...